panitumumab
amgen,takeda
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'improve ']
phii improve in ras/braf wt #mcrc positive and shows #1l intermittent folfiri-pmab (x8 cycles then resumption upon pd) having improved on-tx 1-yr pfs in l-sided tumors, better skin toxicity than continuous folfiri-pmab os data not mature #asco22 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope